Benchmark analyst Bruce Jackson lowered the firm’s price target on Harvard Bioscience (HBIO) to $2 from $3 and keeps a Speculative Buy rating on the shares. Concerns about basic research funding, drug pricing, and tariffs create an uncertain environment for the sector that seems likely to persist for the near future, says the analyst, who cites the heightened risk profile for the firm’s lowered target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- Resilient Performance and Strategic Growth Drive Buy Rating for Harvard Bioscience Amid Market Challenges
- Harvard Bioscience Appoints Stephen DeNelsky to Board
- Harvard Bioscience appoints DeNelsky to board of directors
- Harvard Bioscience Offers CFO $100K Retention Bonus
- Harvard Bioscience at Risk of Nasdaq Delisting: Implications for Investors and Business Stability